September 2026– date –
-
REPROCELL Accelerates Clinical Production with FDA/EMA/PMDA-Compliant iPSC Manufacturing Platform
REPROCELL Japan Overview REPROCELL has unveiled a robust iPSC manufacturing scale-up strategy aimed at accelerating clinical development and commercialization of iPSC-based therapeutics. Their StemRNA™ Clinical iPSC Platform offers clini... -
Notre Dame Develops Machine Learning-Integrated Hybrid 3D Printing for Capillary-Scale Vascular Structures
RegMedNet USA Overview Researchers at the University of Notre Dame have successfully developed a hybrid 3D printing technology integrating machine learning to create capillary-scale microvascular structures. This novel approach demonstra... -
Precision BioSciences Initiates Clinical Trial for ARCUS Nuclease Gene Editing Therapy PBGENE-DMD in DMD
CRISPR Medicine News USA Overview Precision BioSciences has dosed the first patient in its Phase 1/2 clinical trial for PBGENE-DMD, a gene editing therapy for Duchenne muscular dystrophy (DMD). This therapy utilizes two ARCUS nucleases t... -
Novartis Halts CAR T-Cell Trials Following Patient Deaths in Experimental Therapy
pharmaphorum USA Overview Novartis has temporarily halted eight clinical trials for its experimental CAR T-cell therapy, rapcabtagene autoleucel (rap-cel), following the deaths of three patients from immune effector cell-associated hemop... -
Northway Biotech Inaugurates €61 Million Cell Therapy CDMO Facility in Vilnius, First in the Baltics
PR Newswire Lithuania Overview Northway Biotech has invested €61 million to establish the Baltic states' first large-scale Contract Development and Manufacturing Organization (CDMO) facility for cell therapy and personalized medicine in ... -
China Approves Satri-Cel, World’s First CAR T-Cell Therapy for Claudin 18.2-Positive Gastric Cancer
PubMed China Overview China's National Medical Products Administration (NMPA) has approved satricabtagene autoleucel (satri-cel), a CAR T-cell therapy for Claudin 18.2-positive, HER2-negative advanced gastric or gastroesophageal junction... -
REPROCELL Publishes Article on Scaling iPSC Manufacturing: Addressing Challenges from Cell Line Development to Clinical Production
REPROCELL Japan Overview REPROCELL has published an article titled "Scaling iPSC Manufacturing: From Cell Line Development to Clinical Production," focusing on the crucial aspects of industrializing induced pluripotent stem cell (iPSC) t... -
FibroBiologics Secures U.S. Patent (No. 12,721,866) for Wound Healing with 3D Spheroid Fibroblasts, Targeting Chronic and Acute Wounds
Stock Titan USA Overview FibroBiologics announced the issuance of U.S. Patent No. 12,721,866 on September 1, 2026, for the therapeutic use of fibroblasts in wound healing. This patent covers the topical administration of 3D spheroid fibr... -
Hereditary Transthyretin Amyloidosis Market: Intellia/Regeneron’s CRISPR Gene Editor Nexiguran ziclumeran Receives FDA RMAT Designation
GlobeNewswire USA Overview This article summarizes a market research report by DelveInsight on the hereditary transthyretin amyloidosis (hATTR) market. The report highlights Nexiguran ziclumeran (nex-z), a CRISPR-Cas9-based gene-editing ... -
CRISPR-Cas9 Breakthrough: CTX310 Delivers Sustained Lipid Control for Dyslipidemia in Phase 1a Trial, Published in NEJM
The New England Journal of Medicine USA Overview CRISPR Therapeutics' CTX310, a novel CRISPR-Cas9 gene-editing therapy, has demonstrated sustained and profound reductions in key lipid markers—angiopoietin-like 3 (ANGPTL3), triglycerides,...
